These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 32633332)

  • 1. The complement inhibitors in COVID-19: future expectations.
    Korotchaeva Y; Kozlovskaya N; Bobrova L; Kamyshova E; Demyanova K; Moiseev S
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6480-6481. PubMed ID: 32633332
    [No Abstract]   [Full Text] [Related]  

  • 2. Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.
    Stahel PF; Barnum SR
    Front Immunol; 2020; 11():1661. PubMed ID: 32733489
    [No Abstract]   [Full Text] [Related]  

  • 3. Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders.
    Araten DJ; Belmont HM; Schaefer-Cutillo J; Iyengar A; Mattoo A; Reddy R
    Am J Case Rep; 2020 Sep; 21():e927418. PubMed ID: 32917848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Setting Expectations for Clinical Research During the COVID-19 Pandemic.
    Salazar JW; McWilliams JM; Wang TY
    JAMA Intern Med; 2020 Oct; 180(10):1400-1401. PubMed ID: 32716474
    [No Abstract]   [Full Text] [Related]  

  • 5. Tocilizumab for COVID-19: a real 'miracle drug'?
    Nasim S; Hashmi SH; Azim D; Kumar S; Nasim J
    Infect Dis (Lond); 2020 Sep; 52(9):681-682. PubMed ID: 32644027
    [No Abstract]   [Full Text] [Related]  

  • 6. Lung ultrasound signs and cytokine profile in Covid-19 patients: a case series.
    Delrio S; Vetrugno L; Orso D; Deana C; D'Andrea N; Bove T
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8632-8634. PubMed ID: 32964950
    [No Abstract]   [Full Text] [Related]  

  • 7. COVID-19 in an elderly patient treated with secukinumab.
    Di Lernia V; Bombonato C; Motolese A
    Dermatol Ther; 2020 Jul; 33(4):e13580. PubMed ID: 32406078
    [No Abstract]   [Full Text] [Related]  

  • 8. Tocilizumab in COVID-19: Beware the risk of intestinal perforation.
    Vikse J; Henry BM
    Int J Antimicrob Agents; 2020 Jul; 56(1):106009. PubMed ID: 32389721
    [No Abstract]   [Full Text] [Related]  

  • 9. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome.
    Odièvre MH; de Marcellus C; Ducou Le Pointe H; Allali S; Romain AS; Youn J; Taytard J; Nathan N; Corvol H
    Am J Hematol; 2020 Aug; 95(8):E192-E194. PubMed ID: 32358817
    [No Abstract]   [Full Text] [Related]  

  • 10. COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.
    Marchetti M
    Ann Hematol; 2020 Aug; 99(8):1701-1707. PubMed ID: 32583086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
    Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI
    Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985
    [No Abstract]   [Full Text] [Related]  

  • 12. Early tocilizumab treatment could improve survival among COVID-19 patients.
    Campins L; Boixeda R; Perez-Cordon L; Aranega R; Lopera C; Force L
    Clin Exp Rheumatol; 2020; 38(3):578. PubMed ID: 32456769
    [No Abstract]   [Full Text] [Related]  

  • 13. Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.
    Georgakopoulos JR; Yeung J
    J Cutan Med Surg; 2020; 24(4):422-423. PubMed ID: 32434413
    [No Abstract]   [Full Text] [Related]  

  • 14. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.
    Faguer S; Del Bello A; Abravanel F; Nicolau-Travers ML; Kamar N
    Ann Intern Med; 2020 Sep; 173(6):501-503. PubMed ID: 32432518
    [No Abstract]   [Full Text] [Related]  

  • 15. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.
    Mihai C; Dobrota R; Schröder M; Garaiman A; Jordan S; Becker MO; Maurer B; Distler O
    Ann Rheum Dis; 2020 May; 79(5):668-669. PubMed ID: 32241792
    [No Abstract]   [Full Text] [Related]  

  • 16. Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab.
    Suwanwongse K; Shabarek N
    Mult Scler Relat Disord; 2020 Jul; 42():102201. PubMed ID: 32480327
    [No Abstract]   [Full Text] [Related]  

  • 17. Kidney Transplantation and COVID-19.
    Merhi B; Gohh R
    R I Med J (2013); 2020 Sep; 103(8):34-37. PubMed ID: 32900010
    [No Abstract]   [Full Text] [Related]  

  • 18. Who will guard the guards? Covid-19 research may be incomplete, but experts are vital during this pandemic.
    Goh S
    BMJ; 2020 Jul; 370():m2658. PubMed ID: 32620689
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.
    Giovannoni G
    Mult Scler Relat Disord; 2020 Jun; 41():102135. PubMed ID: 32339915
    [No Abstract]   [Full Text] [Related]  

  • 20. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
    Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
    Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.